

To,
The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Fort
Mumbai-Maharashtra 400001

Date: 21st August, 2026

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code: 526546, ISIN: INE493D01013.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") this is to inform you that the United States Food & Drug Administration (USFDA) had inspected Company's central laboratory located at Indore. The inspection was carried on between August 17, 2026 to August 20, 2026.

On conclusion of the inspection, the Company received 4 (Four) observations. We are addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe.

The Company reaffirms its commitment to fully comply with USFDA regulations and to maintain the highest standards of quality and regulatory compliance at all times.

You are requested to take the aforesaid on your record and disseminate the same for information to the public.

Thanking You

Yours faithfully

For Choksi Laboratories Limited

Prakhar Dubey
Company Secretary & Compliance Officer
Mem. No.: A65011